Medindia

X

Amilpar - Relevant Fact - Public Offer

Thursday, December 10, 2009 Corporate News J E 4
Advertisement
RIO DE JANEIRO, Dec. 9 Amilpar (Bovespa: AMIL3;Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest managedcare organization in Brazil, in addition to the Relevant Facts released onNovember 19, 2009 and December 2, 2009, informs its shareholders and themarket that the initiatives to proceed with the Public Offer defined belowwere started today, having as Applicant its subsidiary AMIL ASSISTENCIA MEDICAINTERNACIONAL LTDA. The filing to register the public offer for theacquisition of shares issued by Medial Saude S.A. ("Medial") due to thecontrol change, at the price of R$ 17.2066 per share, along with the exit fromNovo Mercado and delisting of the company was done at CVM - Comissao deValores Mobiliarios (Brazilian Securities and Exchange Commission), accordingto article 254-A of Law 6,404/76, CVM Instruction 361/02, BM&FBovespa's NovoMercado Regulation and the Bylaws of Medial Saude S.A. ("Public Offer").

Amilpar informs that Medial's economic value per share is subject toconfirmation through the valuation report to be prepared according toBM&FBovespa's Novo Mercado rules.

Amilpar will keep the market and its shareholders informed about theconclusion of the above-mentioned offer.To access the Relevant Fact, visit our website at www.amilpar.com.br/ir IR Contact Erwin Kleuser Investor Relations Officer Phone: +55 (21) 3805-1155 invest@amil.com.br www.amilpar.com.br/ir

SOURCE Amilpar
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cutting-Edge Surgery, Seamlessly Performed
S
Confusion Over Homeopathic Medicines in Alexa Ray ...